Takeda considering sale of OTC business in Europe ($11bn)

Takeda Pharmaceuticals is reportedly assessing, jointly with analysts from investment bank JP Morgan, a sale of OTC business in Europe. Selling the asset is likely to offset the debt built up by acquiring Shire for $62bn, indeed it is likely to fetch Takeda $1.1bn, analysts say.

(Source: Bloomberg)